My my best guess would be for approximately 10% higher on the Capex side .....so approx $60 million , and minimum 25% to as high as 40% on the EBIT side . Would also include a possible further positive gain from ' Hidden ' project benefits due to favorable currency exchange variation(s) of at least an additional 10%
So with Top Line improvement to between $825 million and $ 1.125 billion for the 18 year LOM .....which in my view would translate or between AUD $28 million and $32 million AUD of free cashflow each year......... I would have like to see some trading activity today as well as this is just going to look ridiculous come Monday morning IMO. I guess you could say the ' stage is set ' and the ' scene ' is about to unfold for CTM with an appropriate ' re-rate ' excused baked in to any ASX query which may arise next week.
Totally Awesome Folk's.... 1st leg to 1.2 - 1.5 cents locked and loaded......
- Forums
- ASX - By Stock
- Ann: Trading Halt
My my best guess would be for approximately 10% higher on the...
-
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CTM (ASX) to my watchlist
|
|||||
Last
36.5¢ |
Change
0.005(1.39%) |
Mkt cap ! $181.1M |
Open | High | Low | Value | Volume |
37.5¢ | 37.5¢ | 34.5¢ | $146.6K | 408.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 32063 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 3597 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 32063 | 0.350 |
1 | 10000 | 0.340 |
1 | 4450 | 0.335 |
2 | 36000 | 0.330 |
1 | 3000 | 0.320 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 3597 | 1 |
0.370 | 50000 | 1 |
0.375 | 8149 | 1 |
0.390 | 12800 | 1 |
0.400 | 26315 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
CTM (ASX) Chart |